Please note that assistive links (commonly known as "skip to links") are used throughout this site. These links are not well-supported by some mobile devices. If you are encountering difficulty using these links, please navigate around these links, or access the site on a desktop browser.
Skip to the primary content of this page Skip to the footer of this page
Provident Healthcare Partners Provident Healthcare Partners

Q4 2023 Ophthalmology Update

Provident Healthcare Partners
Skip to the end of the Expertise Menu

Q4 2023 Ophthalmology Update

The ophthalmology space continued to experience slower deal flow in the fourth quarter, primarily driven by a shortage of practices exploring a potential sale. Many large-scale practices and private equity-backed platforms have delayed transaction processes due to the tight lending environment and increased cost of debt. As credit markets settle down though, Provident expects the constrained supply to abate in 2024 and valuations to rebound to previously elevated levels.

Given the sector’s position within its investment lifecycle, many platforms that are four to six years within their hold period will likely launch marketing processes of their own in 2024 to explore partnership options. As this “consolidation of consolidators” theme continues to play out, Provident expects 2024 to be a rebound year for M&A activity within the sector.

To print and download the full Ophthalmology Services Update report, please click below…

[holo_button icon=”/wp-content/uploads/2024/01/Q4-2023-Ophthalmology-Newsletter.pdf”” color=”#003561″ target=”blank”]PRINT/DOWNLOAD[/holo_button]